José Ramón Arribas López-rekin lankidetzan egindako argitalpenak (18)

2023

  1. Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)” (EBioMedicine (2020) 55, (S2352396420301547), (10.1016/j.ebiom.2020.102779))

    eBioMedicine

2022

  1. Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance

    Open Forum Infectious Diseases, Vol. 9, Núm. 11

2021

  1. Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 12, pp. 3263-3271

  2. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 3, pp. 738-742

2019

  1. New filovirus disease classification and nomenclature

    Nature Reviews Microbiology

2018

  1. Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens from Patients with Ebola Virus Disease

    Journal of Infectious Diseases

2016

  1. Convalescent plasma for ebola virus disease

    New England Journal of Medicine

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

  3. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus

    Virus Research, Vol. 213, pp. 224-229

2012

  1. Detection and quantification of the K103N mutation in HIV reverse transcriptase by pyrosequencing

    Diagnostic Microbiology and Infectious Disease, Vol. 72, Núm. 1, pp. 90-96

2011

  1. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy

    Antiviral Therapy, Vol. 16, Núm. 5, pp. 725-732

2009

  1. HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 251-258

  2. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis

    Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152

  3. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression

    Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201

2008

  1. Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 6, pp. 1359-1361

  2. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV

    AIDS, Vol. 22, Núm. 2

2006

  1. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone

    AIDS, Vol. 20, Núm. 18, pp. 2331-2335

2005

  1. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-Week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK study)

    Journal of Acquired Immune Deficiency Syndromes, Vol. 40, Núm. 3, pp. 280-287